{"product_id":"tpst-vrio-analysis","title":"Tempest Therapeutics, Inc. (TPST): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Tempest Therapeutics, Inc. (TPST)'s enduring success starts here: this VRIO analysis cuts straight to the chase, evaluating the Value, Rarity, Inimitability, and Organization of its core assets to pinpoint its true competitive advantage. Discover immediately whether Tempest Therapeutics, Inc. (TPST) possesses resources that are truly difficult for rivals to copy and why they matter - read on below to see the full breakdown.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Amezalpat (TPST-1120) Clinical Data and Phase 3 Readiness\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a promising asset in Amezalpat (TPST-1120), but the path from positive Phase 2 data to a launched drug is littered with capital requirements. Here is the breakdown based on the latest data we have through the second half of 2025.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Potential to be a first-in-class oral PPAR$\\alpha$ antagonist for HCC, supported by Phase 2 data showing a six-month median overall survival improvement.\u003c\/h3\u003e\n\u003cp\u003eThe value proposition for Amezalpat is concrete, driven by the Phase 1b\/2 MORPHEUS-LIVER trial results. This oral, selective Peroxisome Proliferator-Activated Receptor alpha (PPAR$\\alpha$) antagonist showed a clear lift over the standard of care (SOC) combination of atezolizumab and bevacizumab. Specifically, the triplet therapy achieved a median Overall Survival (OS) of \u003cstrong\u003e21 months\u003c\/strong\u003e compared to \u003cstrong\u003e15 months\u003c\/strong\u003e for the control group, a \u003cstrong\u003esix-month\u003c\/strong\u003e median improvement. Also, the confirmed Objective Response Rate (ORR) hit \u003cstrong\u003e30%\u003c\/strong\u003e, more than double the control arm’s \u003cstrong\u003e13.3%\u003c\/strong\u003e. That’s real clinical impact.\u003c\/p\u003e\n\u003cp\u003eThe FDA recognized this potential by granting both Orphan Drug Designation in January 2025 and Fast Track designation in February 2025 for this indication. This is the kind of data that gets regulators’ attention.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The specific mechanism targeting PPAR$\\alpha$ in this context, combined with positive Phase 2 data, is relatively unique among late-stage HCC candidates.\u003c\/h3\u003e\n\u003cp\u003eHonestly, the mechanism itself is what sets it apart right now. As of mid-2024, Amezalpat was the \u003cstrong\u003eonly\u003c\/strong\u003e PPAR$\\alpha$ antagonist in active clinical development for oncology. Targeting this pathway to disrupt fatty acid oxidation (FAO) in cancer cells is a distinct approach compared to many other agents in the space. The combination of this unique target and the compelling survival data makes it rare in the current late-stage pipeline.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: The specific clinical data package and the underlying mechanism are hard to copy quickly, but the target pathway itself is known.\u003c\/h3\u003e\n\u003cp\u003eYou can’t just whip up a similar drug overnight. The specific clinical data package - the \u003cstrong\u003e21 months\u003c\/strong\u003e vs. \u003cstrong\u003e15 months\u003c\/strong\u003e OS - is unique to Tempest Therapeutics and is difficult to replicate without running a similar, lengthy trial. However, the underlying target, PPAR$\\alpha$, is a known biological pathway, so a well-funded competitor could eventually pursue similar strategies. The barrier to entry is the successful execution of the clinical program to date, not the pathway itself.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: The company is organized to advance this asset, having completed the end-of-Phase II meeting with the FDA for a Phase 3 study.\u003c\/h3\u003e\n\u003cp\u003eTempest Therapeutics has definitely cleared the organizational hurdles to move forward. They secured broad regulatory agreement with the FDA and EMA on the Phase 3 plan. The global Phase 3 study, TPST-1120-301, was planned to commence patient enrollment in the \u003cstrong\u003efirst quarter of 2025\u003c\/strong\u003e. Plus, they have a supply agreement with Roche to support the trial, which is a big operational plus.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the current state: As of March 31, 2025, the cash position was \u003cstrong\u003e$21.5 million\u003c\/strong\u003e, following a net loss of \u003cstrong\u003e$10.9 million\u003c\/strong\u003e for the first quarter of 2025. What this estimate hides is the massive capital burn required for a global Phase 3 trial, which has been estimated to cost around \u003cstrong\u003e$100 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary, as the Phase 3 trial requires significant funding that is currently uncertain without a partnership.\u003c\/h3\u003e\n\u003cp\u003eRight now, the advantage is \u003cstrong\u003etemporary\u003c\/strong\u003e. The clinical data suggests a sustained competitive advantage is possible, but the immediate hurdle is financial. Tempest is actively exploring strategic alternatives, including partnerships or additional financing, to fund the pivotal development. A recent November 2025 announcement suggested a new acquisition and financing could extend the runway to \u003cstrong\u003emid-2027\u003c\/strong\u003e, but this is contingent on closing and execution. If onboarding for the Phase 3 trial takes longer than expected due to capital constraints, the window to establish a lead shrinks.\u003c\/p\u003e\n\u003cp\u003eHere are the key financial\/operational metrics:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue (as of Q1 2025 or latest)\u003c\/td\u003e\n    \u003ctd\u003eContext\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMedian OS (Amezalpat Arm)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e21 months\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003evs. 15 months control in Phase 2.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eObjective Response Rate (ORR)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003evs. 13.3% control in Phase 2.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$21.5 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAs of March 31, 2025.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePhase 3 Start Plan\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eQ1 2025\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eGlobal study planned.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Status\u003c\/td\u003e\n    \u003ctd\u003eFast Track \u0026amp; ODD\u003c\/td\u003e\n    \u003ctd\u003eGranted in 2025.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: TPST-1495 Dual EP2\/4 Antagonist Program\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eTPST-1495 Dual EP2\/4 Antagonist Program\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eOffers a potential first-in-class oral therapy for Familial Adenomatous Polyposis (FAP), a niche area with no approved medical therapies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFAP prevalence in the US: approximately \u003cstrong\u003e1 in 5,000 to 10,000\u003c\/strong\u003e individuals in the US.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFAP Market Segment\u003c\/td\u003e\n\u003ctd\u003e2024 Value\u003c\/td\u003e\n\u003ctd\u003eProjected 2037 Value\u003c\/td\u003e\n\u003ctd\u003eCAGR (Forecast Period)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall FAP Treatment Market (All Subtypes)\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e2.09 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15.00%\u003c\/strong\u003e (to 2032)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClassic FAP Treatment Market\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e1.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e4.1 billion\u003c\/strong\u003e (by 2037)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8.9%\u003c\/strong\u003e (2025-2037)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutosomal Recessive FAP Treatment Market\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e185.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUSD \u003cstrong\u003e780.6 million\u003c\/strong\u003e (by 2037)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e11.9%\u003c\/strong\u003e (2025-2037)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDual antagonism of EP2\/4 receptors is a specific approach that may offer superior benefit over single-target agents.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe specific molecule and its development pathway are proprietary, but the general target class is being pursued by others.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe Phase 2 trial is structured to be run by the Cancer Prevention Clinical Trials Network, leveraging external infrastructure.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA granted Orphan Drug Designation for TPST-1495 for FAP treatment.\u003c\/li\u003e\n\u003cli\u003eOrphan Drug Designation benefits include tax credits for clinical testing, potential fee waivers for FDA applications, and \u003cstrong\u003eseven years\u003c\/strong\u003e of market exclusivity if approved.\u003c\/li\u003e\n\u003cli\u003eReceived FDA “Study May Proceed” letter for the Phase 2 trial.\u003c\/li\u003e\n\u003cli\u003ePhase 2 study expected to begin in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData from the Phase 2 study expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTrial is financially supported by the NCI's Division of Cancer Prevention.\u003c\/li\u003e\n\u003cli\u003ePrimary efficacy objective: assess activity in reducing duodenal polyp burden after \u003cstrong\u003e6 months\u003c\/strong\u003e of treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary, contingent on successful Phase 2 data expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Strategic Acquisition of Dual-CAR T Programs (TPST-2003)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eDiversifies pipeline with TPST-2003, a clinical-stage CD19\/BCMA Dual-CAR T program targeting extramedullary disease (EMD) in relapsed multiple myeloma (rrMM). Expected data milestones include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 data for rrMM expected in \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePhase 1 data for POEMs syndrome expected in \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential registrational study in rrMM in the U.S. planned to start in \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eAcquisition of a clinical-stage CAR-T asset via an all-stock deal during a period where biopharma financings were down \u003cstrong\u003e59%\u003c\/strong\u003e in the first half of 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Issued to Factor Affiliate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8,268,495\u003c\/strong\u003e new shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFactor Affiliate Ownership Post-Close\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e65.0%\u003c\/strong\u003e of total equity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Closing Tempest Stockholder Ownership Post-Close\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e35.0%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Exercise Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.48\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Term\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFive-year\u003c\/strong\u003e expiration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific Factor Bioscience assets and deal terms are unique to this transaction, which includes the transfer of global rights to TPST-2003 outside of China, India, Turkey, and Russia.\u003c\/p\u003e\n\u003cp\u003eThe transaction structure includes a change in executive leadership and specific compensation details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNew President and CEO Matt Angel's annual base salary: \u003cstrong\u003e$650,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew President and CEO Matt Angel's annual target bonus: \u003cstrong\u003e50%\u003c\/strong\u003e of base salary (or \u003cstrong\u003e$325,000\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eOutgoing CEO Stephen Brady's annual salary: \u003cstrong\u003e$600,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe acquisition was executed with a simultaneous financing commitment designed to extend the financial runway to \u003cstrong\u003emid-2027\u003c\/strong\u003e. A closing condition requires a pre-closing equity financing to generate gross proceeds of at least \u003cstrong\u003e$5.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFinancial context at the time of the announcement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents at end of Q3: \u003cstrong\u003e$7.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNegative EBITDA (last twelve months): \u003cstrong\u003e$36.17 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: \u003cstrong\u003e2.3\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization (at announcement): \u003cstrong\u003e$41 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003c\/p\u003e\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained advantage is contingent on successful integration and clinical progression of the acquired cell therapy platform alongside existing assets like amezalpat (Phase 3-ready PPAR$\\alpha$ Antagonist) and TPST-1495 (Phase 2 start expected near term).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Collaboration with Roche for Amezalpat\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe collaboration, announced on October 10, 2024, provides access to a powerhouse partner for clinical study execution and supply of Tecentriq (Atezolizumab) for the planned pivotal HCC trial. Roche will supply Atezolizumab globally for the Phase 3 study. Tempest retains all commercial and development rights to Amezalpat. The combination therapy demonstrated a six-month improvement in median overall survival (OS) in the Phase 1b\/2 study compared to the control arm.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmezalpat Combination (TPST-1120 + Tecentriq + Avastin)\u003c\/th\u003e\n\u003cth\u003eControl Arm (Tecentriq + Avastin)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Overall Survival (OS) Improvement\u003c\/td\u003e\n\u003ctd\u003eSix months greater than control\u003c\/td\u003e\n\u003ctd\u003eBaseline for comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian OS (Reported Figure)\u003c\/td\u003e\n\u003ctd\u003e21 months\u003c\/td\u003e\n\u003ctd\u003e15 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Milestone\u003c\/td\u003e\n\u003ctd\u003eFDA agreement on Phase 3 design in August 2024\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eA collaboration with a major pharmaceutical company like Roche on a lead asset is a significant de-risking factor, especially given that Amezalpat is a clinical PPAR$\\alpha$ antagonist with no currently approved competitors in this class by the FDA.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmezalpat has been granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) for the treatment of HCC.\u003c\/li\u003e\n\u003cli\u003eThe Phase 3 study timeline could potentially be shortened by eight months due to a pre-specified early efficacy analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe specific terms and history of the collaboration are unique to TPST. The current agreement builds upon a previous clinical partnership dating back to 2021. The positive data supporting the move to Phase 3 includes:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eConsistent survival benefit across key subpopulations.\u003c\/li\u003e\n\u003cli\u003eIncreased objective response rate in patients with a beta-catenin gene mutation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eTempest remains the principal sponsor and leads the pivotal study, retaining all development and commercial rights to Amezalpat, which is a strong organizational control point. The company ended the 2024 fiscal year with $30.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023. Roche's Tecentriq generated sales of $2.14 billion for Roche in 2024.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained, as long as the collaboration agreement remains in effect and provides value, leveraging Roche's supply of Atezolizumab (Tecentriq), a drug with $2.14 billion in 2024 sales for Roche. Tempest's Net Loss for the year 2024 was $41.8 million, with Research and Development expenses at $28.5 million.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Regulatory Incentives: Orphan Drug and Fast Track Designations\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e These designations (for Amezalpat and TPST-1495) offer potential market exclusivity periods and development incentives, boosting commercial value.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDesignation Type\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eRegulatory Body\u003c\/th\u003e\n\u003cth\u003eSupporting Efficacy Data (Amezalpat HCC)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmezalpat (TPST-1120)\u003c\/td\u003e\n\u003ctd\u003eFast Track Designation (FTD)\u003c\/td\u003e\n\u003ctd\u003eHepatocellular Carcinoma (HCC)\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eMedian Overall Survival (OS) of \u003cstrong\u003e21 months\u003c\/strong\u003e vs \u003cstrong\u003e15 months\u003c\/strong\u003e (Standard of Care)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmezalpat (TPST-1120)\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD)\u003c\/td\u003e\n\u003ctd\u003eHepatocellular Carcinoma (HCC)\u003c\/td\u003e\n\u003ctd\u003eFDA, EMA\u003c\/td\u003e\n\u003ctd\u003eHazard Ratio (HR) of \u003cstrong\u003e0.65\u003c\/strong\u003e for OS benefit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTPST-1495\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation (ODD)\u003c\/td\u003e\n\u003ctd\u003eFamilial Adenomatous Polyposis (FAP)\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eN\/A (Data not specified in context)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Achieving multiple key designations across different assets is uncommon for a company of this size.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company secured ODD for two distinct pipeline assets: Amezalpat and TPST-1495.\u003c\/li\u003e\n\u003cli\u003eAmezalpat received both ODD and FTD from the FDA, accelerating its path for a serious condition with unmet medical need.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Regulatory designations are granted by agencies and cannot be imitated, only earned through data submission.\u003c\/p\u003e\n\u003cp\u003eThe FTD for Amezalpat was granted based on positive data from the global randomized Phase 1b\/2 MORPHEUS-LIVER trial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The regulatory team successfully navigated the FDA and EMA processes to secure these valuable statuses.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Orphan Drug Designation (ODD) for Amezalpat granted in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA Fast Track Designation (FTD) for Amezalpat granted on \u003cstrong\u003eFebruary 10, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA Orphan Drug Designation (ODD) granted for TPST-1495.\u003c\/li\u003e\n\u003cli\u003eEMA Orphan Drug Designation for Amezalpat also secured.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained for the duration of the exclusivity period granted by the regulatory bodies.\u003c\/p\u003e\n\u003cp\u003eThe FTD allows for an expedited review process with the eventual goal of full FDA approval.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Focused R\u0026amp;D and Cost Management Strategy\n\u003c\/h2\u003e\n\u003cp\u003e\nThe analysis focuses on the strategic financial realignment executed by Tempest Therapeutics, Inc.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2025\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.79\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.32\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$30.3 million\u003c\/strong\u003e (as of December 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eFocused R\u0026amp;D and Cost Management Strategy\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nValue:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReduced Q3 2025 Research and Development expenses to just \u003cstrong\u003e$0.6 million\u003c\/strong\u003e from \u003cstrong\u003e$7.6 million\u003c\/strong\u003e in Q3 2024, resulting in a quarterly decrease of \u003cstrong\u003e$7.0 million\u003c\/strong\u003e, preserving capital.\u003c\/li\u003e\n\u003cli\u003eYear-to-date Research and Development expenses for the nine months ended September 30, 2025, were \u003cstrong\u003e$12.1 million\u003c\/strong\u003e, down from \u003cstrong\u003e$17.7 million\u003c\/strong\u003e in the same period in 2024.\u003c\/li\u003e\n\u003cli\u003eNet loss for Q3 2025 narrowed to \u003cstrong\u003e$3.5 million\u003c\/strong\u003e from \u003cstrong\u003e$10.6 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nRarity:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe sharp, strategic reduction in R\u0026amp;D spending by \u003cstrong\u003e$7.0 million\u003c\/strong\u003e quarter-over-quarter, while maintaining focus on key assets, demonstrates focused operational discipline.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nImitability:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe specific cost structure and spending priorities, driven by the decision to explore strategic alternatives, are internal operational decisions not easily copied by competitors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nOrganization:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement demonstrated the ability to pivot quickly, pausing projects to focus on the Phase 2 trial for \u003cstrong\u003eTPST-1495\u003c\/strong\u003e in collaboration with the NCI.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing \u003cstrong\u003eTPST-1495\u003c\/strong\u003e into a Phase 2 study for Familial Adenomatous Polyposis (FAP) under the auspices of the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTemporary, as R\u0026amp;D spending must eventually increase to advance the pipeline past Phase 2\/3 milestones for assets like amezalpat (\u003cstrong\u003eTPST-1120\u003c\/strong\u003e) in first-line HCC.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents decreased to \u003cstrong\u003e$7.5 million\u003c\/strong\u003e by September 30, 2025, from \u003cstrong\u003e$30.3 million\u003c\/strong\u003e at the end of 2024, indicating pressure on the financial runway supporting future development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Extended Financial Runway to Mid-2027\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eExtended Financial Runway to Mid-2027\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The combination of the all-stock acquisition and the investment commitment from Factor Bioscience is projected to extend Tempest Therapeutics' cash runway to \u003cstrong\u003emid-2027\u003c\/strong\u003e. This funding is anticipated to cover key development phases and data milestones slated for \u003cstrong\u003e2026\u003c\/strong\u003e and \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Securing a runway extension to \u003cstrong\u003emid-2027\u003c\/strong\u003e through a simultaneous all-stock acquisition and an investment commitment from the counterparty (Factor) represents a significant achievement in the \u003cstrong\u003elate 2025\u003c\/strong\u003e funding climate.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific financing structure, which couples an asset acquisition with a runway extension commitment via an investment from the seller, is unique to TPST's situation following the announcement on November 19, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company executed a complex transaction involving the acquisition of clinical-stage CD19\/BCMA Dual-CAR T programs (TPST-2003) and securing financing concurrently to address cash burn and fund operations through \u003cstrong\u003emid-2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the extended runway is finite and contingent upon hitting value-creating milestones or securing further financing beyond \u003cstrong\u003emid-2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eKey financial and transaction metrics supporting the runway extension:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Timing\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eWith existing cash and Factor investment commitment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProposed Transaction Structure\u003c\/td\u003e\n\u003ctd\u003eAll-stock transaction\u003c\/td\u003e\n\u003ctd\u003eAcquisition of CAR-T programs from Factor Bioscience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Transaction Closing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEarly 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubject to stockholder approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired Asset\u003c\/td\u003e\n\u003ctd\u003eTPST-2003\u003c\/td\u003e\n\u003ctd\u003eClinical-stage CD19\/BCMA Dual-CAR T program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Data Milestone (TPST-2003)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePhase 1 data expected for relapsed multiple myeloma (rrMM)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey BLA Target (TPST-2003)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2027\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eChina Biologics License Application (BLA) planned for rrMM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Market Capitalization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$40.49M\u003c\/strong\u003e - \u003cstrong\u003e$41.03M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReported figures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Short-Term Investments (Prior Period Example)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.27M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of a reported period end (e.g., Dec '24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe pipeline expansion includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcquisition of TPST-2003, a clinical-stage CD19\/BCMA dual-CAR T program designed for extramedullary disease (EMD).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExpansion of the existing pipeline which includes amezalpat (TPST-1120), which is Phase 3-ready, and TPST-1495, with a Phase 2 start expected near term.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003ePotential to pursue a registrational study in rrMM in the U.S. starting in \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: New Leadership with Cell Therapy and IP Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eNew Leadership with Cell Therapy and IP Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe incoming President and CEO, Dr. Matt Angel, brings deep expertise in cell therapy development and holds over \u003cstrong\u003e150 patents\u003c\/strong\u003e covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eA CEO with such a strong, relevant scientific and intellectual property background is rare, especially following a major cell therapy acquisition. Dr. Angel previously led Factor Bioscience Inc. as co-founder and CEO since \u003cstrong\u003e2011\u003c\/strong\u003e and led Brooklyn Immunotherapeutics as CEO from \u003cstrong\u003e2022-2023\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe specific combination of Dr. Angel's background and the existing team is not easily replicated. Dr. Angel is a co-founder of cell therapy companies Novellus Therapeutics (founded \u003cstrong\u003e2014\u003c\/strong\u003e; sold \u003cstrong\u003e2021\u003c\/strong\u003e) and Exacis Biotherapeutics (founded \u003cstrong\u003e2020\u003c\/strong\u003e; sold \u003cstrong\u003e2023\u003c\/strong\u003e).\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe management transition is timed with the strategic acquisition, aligning leadership with the expanded, diversified pipeline. The all-stock transaction to acquire dual-targeting CAR-T programs from Factor Bioscience is expected to close in \u003cstrong\u003eearly 2026\u003c\/strong\u003e. The company expects existing cash and an investment commitment from Factor to extend its operational runway to \u003cstrong\u003emid-2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained, as leadership quality and IP strategy are foundational to long-term value creation.\u003c\/p\u003e\n\u003cp\u003eKey Data Points Related to Leadership and Pipeline Expansion:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eDetail\/Value\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDr. Angel's Patent Count\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e150\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Closing Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEarly 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Runway Extension\u003c\/td\u003e\n\u003ctd\u003eTo \u003cstrong\u003emid-2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Structure\u003c\/td\u003e\n\u003ctd\u003eAll-stock transaction; Tempest to issue \u003cstrong\u003e8,268,495\u003c\/strong\u003e shares of common stock to Factor\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired Asset (CAR-T)\u003c\/td\u003e\n\u003ctd\u003eTPST-2003 (clinical-stage CD19\/BCMA dual-CAR T)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExisting Pipeline Asset (Phase 3-ready)\u003c\/td\u003e\n\u003ctd\u003eAmezalpat (TPST-1120)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExisting Pipeline Asset (Phase 2 start)\u003c\/td\u003e\n\u003ctd\u003eTPST-1495 (Dual Ep2\/4 Antagonist)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe expanded pipeline now includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTPST-2003: Clinical-stage CD19\/BCMA dual-CAR T program targeting extramedullary disease (EMD).\u003c\/li\u003e\n\u003cli\u003eAmezalpat (TPST-1120): PPAR$\\alpha$ antagonist, Phase 3-ready, with positive data showing a six-month improvement in median overall survival (OS) in first-line HCC when combined with atezolizumab and bevacizumab compared to standard of care alone.\u003c\/li\u003e\n\u003cli\u003eTPST-1495: Dual Ep2\/4 Antagonist, Phase 2 start expected near term. Received Orphan Drug Designation in \u003cstrong\u003eMarch 2025\u003c\/strong\u003e for Familial Adenomatous Polyposis (FAP).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTempest Therapeutics, Inc. (TPST) - VRIO Analysis: Platform for Targeted and Immune-Mediated Small Molecule Therapies\n\u003c\/h2\u003e\n\n\u003cp\u003eThe analysis below is based on the platform underpinning candidates such as Amezalpat (TPST-1120) and TPST-1495.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eThe core scientific platform allows for the development of oral therapeutics that can directly kill tumor cells or activate immunity.\u003c\/td\u003e\n\u003ctd\u003eAmezalpat (TPST-1120) is a first-in-class oral PPAR$\\alpha$ antagonist showing dual mechanisms: inhibition of FAO gene expression and reversal of immune suppression via NF-kB.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eThe dual mechanism approach (tumor-targeted AND immune-mediated) across multiple small molecule candidates is a distinct scientific focus.\u003c\/td\u003e\n\u003ctd\u003eAmezalpat is the only PPAR$\\alpha$ antagonist in active clinical development in oncology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eThe underlying scientific knowledge and validated pathways are proprietary, though the field is competitive.\u003c\/td\u003e\n\u003ctd\u003eAmezalpat demonstrated median overall survival (OS) of over 21 months (HR 0.65) in a triplet therapy vs. 15 months for the standard of care doublet in first-line advanced HCC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eThis platform underpins the entire portfolio, from Amezalpat to TPST-1495, showing consistent scientific direction.\u003c\/td\u003e\n\u003ctd\u003eTPST-1495 is a potential orally bioavailable first-in-class EP2\/4 dual antagonist planned for a Phase 2 study in Familial Adenomatous Polyposis (FAP).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained, as long as the platform continues to generate novel, differentiated candidates.\u003c\/td\u003e\n\u003ctd\u003eAmezalpat received both Orphan Drug and Fast Track designations from the FDA for hepatocellular carcinoma (HCC).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eFinance: Inputs for 13-Week Cash Flow Projection\u003c\/h\u003e\n\u003cp\u003eThe projection is drafted incorporating the following latest reported financial figures as of the end of Q3 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents balance as of September 30, 2025: \u003cstrong\u003e$7.5 million\u003c\/strong\u003e,.\u003c\/li\u003e\n\u003cli\u003eNet proceeds from June 2025 registered direct offering (YTD Q3 2025): \u003cstrong\u003e$4.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet proceeds from at-the-market offering program (YTD Q3 2025): \u003cstrong\u003e$2.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal net proceeds from financing activities reported for the nine months ended September 30, 2025: The sum of the two noted proceeds is \u003cstrong\u003e$6.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash used in operating activities for the nine months ended September 30, 2025: \u003cstrong\u003e$23.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516269224085,"sku":"tpst-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/tpst-vrio-analysis.png?v=1740220974","url":"https:\/\/dcf-model.com\/pt\/products\/tpst-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}